These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32308867)

  • 1.
    Portanova J; Murray N; Mower J; Subramanian D; Cohen T
    AMIA Annu Symp Proc; 2019; 2019():717-726. PubMed ID: 32308867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmenting aer2vec: Enriching distributed representations of adverse event report data with orthographic and lexical information.
    Ding X; Mower J; Subramanian D; Cohen T
    J Biomed Inform; 2021 Jul; 119():103833. PubMed ID: 34111555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Drug Blood-Brain Barrier Penetration with Adverse Event Report Embeddings.
    Wu Y; Mower J; Ding X; Li O; Subramanian D; Cohen T
    AMIA Annu Symp Proc; 2022; 2022():1163-1172. PubMed ID: 37128462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrofitting Vector Representations of Adverse Event Reporting Data to Structured Knowledge to Improve Pharmacovigilance Signal Detection.
    Ding X; Cohen T
    AMIA Annu Symp Proc; 2020; 2020():383-392. PubMed ID: 33936411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel C; Scosyrev E; Petrin M; Schmouder R
    Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
    Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
    Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
    Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
    Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing an Artificial Intelligence-Guided Signal Detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A Proof-of-Concept Study Using Galcanezumab and Simulated Data.
    Al-Azzawi F; Mahmoud I; Haguinet F; Bate A; Sessa M
    Drug Saf; 2023 Aug; 46(8):743-751. PubMed ID: 37300636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementing Observational Signals with Literature-Derived Distributed Representations for Post-Marketing Drug Surveillance.
    Mower J; Cohen T; Subramanian D
    Drug Saf; 2020 Jan; 43(1):67-77. PubMed ID: 31646442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hierarchy-aware Adverse Reaction Embeddings for Signal Detection.
    Joopudi V; Dandala B; Tsou CH; Liang JJ
    AMIA Annu Symp Proc; 2022; 2022():596-605. PubMed ID: 37128452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning.
    Arku D; Yousef C; Abraham I
    Expert Opin Drug Saf; 2022 Oct; 21(10):1235-1238. PubMed ID: 36181369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A curated and standardized adverse drug event resource to accelerate drug safety research.
    Banda JM; Evans L; Vanguri RS; Tatonetti NP; Ryan PB; Shah NH
    Sci Data; 2016 May; 3():160026. PubMed ID: 27193236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification-by-Analogy: Using Vector Representations of Implicit Relationships to Identify Plausibly Causal Drug/Side-effect Relationships.
    Mower J; Subramanian D; Shang N; Cohen T
    AMIA Annu Symp Proc; 2016; 2016():1940-1949. PubMed ID: 28269953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
    Kuehn BM
    JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
    [No Abstract]   [Full Text] [Related]  

  • 18. Miscategorization of Deaths in the US Food and Drug Administration Adverse Events Database.
    Meier L; Wang EY; Tomes M; Redberg RF
    JAMA Intern Med; 2020 Jan; 180(1):147-148. PubMed ID: 31589249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA Sentinel Initiative - An Evolving National Resource.
    Platt R; Brown JS; Robb M; McClellan M; Ball R; Nguyen MD; Sherman RE
    N Engl J Med; 2018 Nov; 379(22):2091-2093. PubMed ID: 30485777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.